Hematologic Cancers

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

By

First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

By

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

By

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

By

The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.

Higher-Dose Immunoglobulin Replacement Therapy  in Chronic Lymphocytic Leukemia

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

By

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

By

Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

By

Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.

Feasibility of Clinical Production of Autologous NKG2D CAR-T

Feasibility of Clinical Production of Autologous NKG2D CAR-T

By

The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

By

Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

By

Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.

All CAR Signaling Domains in Lymphoma Are Not Created Equal

All CAR Signaling Domains in Lymphoma Are Not Created Equal

By

Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

By

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

By

Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.

Liquid Biopsy May Predict Response to Therapy in Diffuse Large B-Cell Lymphoma

Liquid Biopsy May Predict Response to Therapy in Diffuse Large B-Cell Lymphoma

By

Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

By

The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.

Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma

Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma

By

Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.

Measurement of Excess Abdominal Fat, Not BMI, May Be a More Accurate Risk Factor for Blood Cancers

Measurement of Excess Abdominal Fat, Not BMI, May Be a More Accurate Risk Factor for Blood Cancers

By

Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

By

The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.

Evaluation of Available Frontline Induction Therapies for Multiple Myeloma

Evaluation of Available Frontline Induction Therapies for Multiple Myeloma

By

There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.

Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?

Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?

By

Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.

Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia

Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia

By

Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.

Obinutuzumab in Follicular Lymphoma

Obinutuzumab in Follicular Lymphoma

By

Many patients with follicular lymphoma will be asymptomatic and present with variable cervical, axillary, and inguinal adenopathy.

Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia

Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia

By

New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.

Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia

Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia

By

Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Selinexor and Multiple Myeloma

Selinexor and Multiple Myeloma

By

Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.

Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

By

Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.

Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

By

No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs